Abstract
Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Oral GP Ilb/IHa inhibitors may offer an opportunity to expand the application of this therapy to additional vascular indications and to extend therapy beyond the in‐hospital period. A number of oral GP IIb/IIIa inhibiting agents have been evaluated; however, no benefit has been observed. Oral GP IIb/IIIa inhibitors have been associated with an increased incidence of bleeding, but additional experience may permit the design of dosing regimens that decrease this risk. The recent Orbofiban in Patients with Unstable Coronary Syndromes (OPUS/TIMI‐16) trial showed a small but significant increase in mortality in orbofiban‐treated patients. It appears that this agent, and perhaps other oral GP IIb/IIIa inhibitors including sibrafiban and xemilofiban, may have a pro‐aggregatory effect. This may be caused by the drug dissociating from the GP IIb/IIIa receptor, leaving an activated receptor that can then bind fibrinogen and form a platelet aggregate. Further studies are needed to elucidate the mechanism of this effect and to evaluate whether the second‐generation of oral GP IIb/IIIa inhibitors, which have tight binding and a longer duration of antiplatelet effect, will be of clinical benefit.
Keywords: oral glycoprotein IIb/IIIa receptor antagonists, OPUS/TIMI‐16, platelet aggregation stimulation, platelet aggregation inhibitors, orbofiban, fibrinogen binding, P‐selectin
Full Text
The Full Text of this article is available as a PDF (417.6 KB).
References
- 1. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829–2835 [DOI] [PubMed] [Google Scholar]
- 2. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E: Platelet activation in patients after an acute coronary syndrome: Results from the TIMI‐12 trial. J Am Coll Cardiol 1999; 33: 634–639 [DOI] [PubMed] [Google Scholar]
- 3. CAPTURE Investigators : Randomised placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435 [PubMed] [Google Scholar]
- 4. EPIC Investigators : Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high‐risk coronary angioplasty. N Engl J Med 1994; 330: 956–961 [DOI] [PubMed] [Google Scholar]
- 5. EPILOG Investigators : Platelet glycoprotein IIb/IIIa receptor blockade and low‐dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696 [DOI] [PubMed] [Google Scholar]
- 6. The IMPACT‐II Investigators : Randomised placebo‐controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT‐II. Lancet 1997; 349: 1422–1428 [PubMed] [Google Scholar]
- 7. The RESTORE Investigators : Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453 [DOI] [PubMed] [Google Scholar]
- 8. The PURSUIT Trial Investigators : Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443 [DOI] [PubMed] [Google Scholar]
- 9. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM‐PLUS) Study Investigators : Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497 [DOI] [PubMed] [Google Scholar]
- 10. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmed ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, for the TIMI 12 Investigators: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 1998; 97: 340–349 [DOI] [PubMed] [Google Scholar]
- 11. Cannon CP, McCabe CH, Wilcox RG, Charlesworth A, Foxley A, Anders RJ, Alexander JC, Braunwald E: Oral IIb/IIIa inhibition and revascularization: Preliminary results from OPUS‐TIMI 16 (Orbofiban in patients with unstable coronary syndromes) (abstr 2626). Circulation 1999; 100 (18 suppl I): I–498 [Google Scholar]
- 12. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez‐Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS‐TIMI 16) trial. Circulation 2000; 102: 149–156 [DOI] [PubMed] [Google Scholar]
- 13. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb‐IIIa blockers. Lancet 1999; 353: 227–231 [DOI] [PubMed] [Google Scholar]
- 14. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R, for the EXCITE Trial Investigators: Long‐term treatment with a platelet glycoprotein‐receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000: 342: 1316–1324 [DOI] [PubMed] [Google Scholar]
- 15. The SYMPHONY Investigators : Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Lancet 2000; 355: 337–345 [PubMed] [Google Scholar]
- 16. Newby K: A randomized comparison of sibrafiban, an oral glycoprotein IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes: Results of the 2nd SYMPHONY trial. Medscape 2000.
- 17. Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C: Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbb̃3) inhibitors. Blood 1998; 92: 3240–3249 [PubMed] [Google Scholar]
- 18. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ: Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514–1519 [DOI] [PubMed] [Google Scholar]
- 19. Holmes MB, Sobel BE, Cannon CP, Schneider DJ : Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS‐TIMI 16 substudy. Am J Cardiol 2000; 85: 491–493 [DOI] [PubMed] [Google Scholar]
- 20. Moussa I, Traube E, Roubin G, Colombo A, Iyer S, New G, Al‐Mubarak N, Collins M, Kreps E, Moses J: The impact of oral antiplatelet therapy on CK release after coronary stent implantation: A comparison between ticlopidine and clopidogrel (abstr 1153‐118). J Am Coll Cardiol 2000; 35 (suppl A): 67A 10636261 [Google Scholar]
- 21. Langer A, Goodman SG, Reilly TM, Mousa SA, Racanelli AL, O'Connor C, O'Neill WW, Kleiman NS, Gurbel P, Daly RN: Second generation oral IIb/IIIa receptor blockade: Phase II experience with roxifiban (abstr 1158‐11). J Am Coll Cardiol 2000; 35 (suppl A): 308A 10676674 [Google Scholar]